TABLE 2.
Main HDAC inhibitors which have beneficial effect against cardiac hypertrophy.
| HDAC inhibitor | Type | Target HDAC type | References |
| TSA | Hydroxamic acid | HDAC2, 3 | (132, 145–148) |
| VPA | Short-chain fatty acid | HDAC1, 2, 6, 8 | (145, 147, 149) |
| CBHA | Hydroxamic | Unclear | (150) |
| MGCD0103 | Benzamide | Class I, IV | (126) |
| RGFP966 | Benzamide | HDAC3 | (151) |
| Apicidin | Cyclic peptide | HDAC1, 2, 3 | (136) |
| NaB | Short-chain fatty acid | HDAC2, 4, 5, 6 | (135) |
| SK-7041 | Hydroxamic acid | Class I | (6) |
| SAHA | Hydroxamic acid | Class I, IV | (152) |
| Romidepsin | Cyclic peptide | Class I | (153) |
CBHA, m-carboxycinnamic acid bishydroxamide; ITF2357, Givinostat; MGCD0103, mocetinostat; NaB, sodium butyrate; SAHA, suberanilo hydroxamic acid, vorinostat; TSA, trichostatin A; VPA, valproic acid.